Ⅲa-N2期非小細(xì)胞肺癌新輔助化療后胸腔鏡手術(shù)與開胸手術(shù)的比較
發(fā)布時(shí)間：2019-03-25 17:50
【摘要】：背景和目的:可手術(shù)局部晚期(Ⅲa-N2期)非小細(xì)胞肺癌新輔助化療后病變情況較早期肺癌更為復(fù)雜,常規(guī)需采用開胸手術(shù),該類患者能否施行胸腔鏡手術(shù)?在技術(shù)上和安全性上是否可行?較傳統(tǒng)開胸手術(shù)是否有優(yōu)勢(shì)?目前國(guó)內(nèi)外仍存在廣泛爭(zhēng)議。本研究通過對(duì)臨床分期Ⅲa-N2期非小細(xì)胞肺癌新輔助化療后胸腔鏡手術(shù)與開胸手術(shù)的前瞻性隨機(jī)對(duì)照研究,探討臨床分期Ⅲa-N2期非小細(xì)胞肺癌新輔助化療后行胸腔鏡肺葉切除術(shù)的安全性和可行性,并總結(jié)手術(shù)經(jīng)驗(yàn)。方法:本研究選擇2012年6月~2016年6月初診臨床分期Ⅲa-N2期已行新輔助化療并擬行肺葉切除術(shù)的非小細(xì)胞肺癌患者40例,隨機(jī)分兩組:研究組20例行胸腔鏡肺葉切除+系統(tǒng)性淋巴結(jié)清掃術(shù);對(duì)照組20例行傳統(tǒng)開胸肺葉切除+系統(tǒng)性淋巴結(jié)清掃術(shù)。比較兩組手術(shù)時(shí)間、術(shù)中出血量、引流管留置時(shí)間、淋巴結(jié)清掃數(shù)目、術(shù)后并發(fā)癥、術(shù)后住院天數(shù)、術(shù)后VAS疼痛評(píng)分。結(jié)果:研究組有17例完成胸腔鏡肺葉切除術(shù),1例(1/20,5%)行胸腔鏡探查術(shù),中轉(zhuǎn)行開胸肺葉切除術(shù)2例(2/20,10%);傳統(tǒng)開胸組20例均順利完成肺葉切除術(shù)。兩組患者無圍手術(shù)期死亡。兩組手術(shù)時(shí)間:研究組165.47±30.54分,對(duì)照組152.53±35.65分。術(shù)中出血:研究組187.35±90.93m L,對(duì)照組210.29±98.02mL。胸管留置時(shí)間:研究組5.42±2.49天,對(duì)照組5.35±3.18天。淋巴結(jié)清掃數(shù)目:研究組9.59±2.32個(gè),對(duì)照組9.47±2.03個(gè)。術(shù)后并發(fā)癥:研究組2例(11.8%),對(duì)照組6例(30.0%)。術(shù)后住院天數(shù):研究組7.35±2.03天,對(duì)照組10.12±2.32天。兩組患者手術(shù)時(shí)間、術(shù)中出血量、引流管留置時(shí)間、淋巴結(jié)清掃數(shù)目差異無統(tǒng)計(jì)學(xué)意義(P0.05);研究組術(shù)后并發(fā)癥發(fā)生率及VAS疼痛評(píng)分更低、住院天數(shù)更短,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:臨床分期Ⅲa-N2期非小細(xì)胞肺癌新輔助化療后行胸腔鏡肺葉切除手術(shù)治療是安全的、可行的,較傳統(tǒng)開胸手術(shù)具有一定的微創(chuàng)優(yōu)勢(shì)。臨床分期Ⅲa-N2期非小細(xì)胞肺癌患者新輔助化療后胸腔鏡手術(shù),應(yīng)在化療后進(jìn)行精確的療效評(píng)估和手術(shù)可行性評(píng)估,選擇合適的病例施行,化療療效較好、無明顯腫大融合并侵犯肺門縱膈結(jié)構(gòu)淋巴結(jié)者可以選擇胸腔鏡手術(shù)。術(shù)前肺內(nèi)N1淋巴結(jié)是否包繞粘連肺內(nèi)支氣管血管的準(zhǔn)確評(píng)估也是能否選擇胸腔鏡手術(shù)的關(guān)鍵技術(shù)點(diǎn)�？v膈淋巴結(jié)清掃應(yīng)采用enbloc切除技術(shù)即整塊切除技術(shù),應(yīng)避免淋巴結(jié)采樣。
[Abstract]:BACKGROUND & OBJECTIVE: The patients with advanced non-small cell lung cancer (NSCLC) with advanced non-small cell lung cancer (NSCLC) with advanced non-small cell lung cancer are more complicated than the early stage of lung cancer. Is technically and safely possible? Is there an advantage over the traditional thoracotomy? There are still a wide range of disputes at home and abroad. The purpose of this study was to investigate the safety and feasibility of a new adjuvant chemotherapy for non-small cell lung cancer in stage 鈪-N2 non-small cell lung cancer after neoadjuvant chemotherapy, and to evaluate the safety and feasibility of thoracoscopic pulmonary lobectomy after neoadjuvant chemotherapy in stage 鈪-N2 non-small cell lung cancer. And summarize the experience of the operation. Methods:40 patients with non-small cell lung cancer who received neoadjuvant chemotherapy in stage 鈪-N2 and non-small cell lung cancer with pulmonary lobectomy were selected from June 2012 to June 2016, and two groups were randomly divided into two groups:20 patients in the study group and 20 patients with systematic lymph node dissection; In the control group,20 cases of conventional thoracotomy + systematic lymph node dissection were performed. The operative time, the intraoperative blood loss, the indwelling time of the drainage tube, the number of lymph node dissection, the postoperative complications, the number of postoperative hospital stay and the VAS pain score were compared. Results: In the study group,17 cases underwent thoracoscopic lobectomy, one case (1/20,5%) underwent thoracoscopic exploration, and 2 cases (2/20,10%) of transthoracic and pulmonary lobectomy were performed in the study group, and 20 cases of the traditional thoracotomy group successfully completed the lobectomy. There were no perioperative deaths in both groups. The operation time of the two groups was 165.47 and 30.54 in the study group, and the control group was 152.53 to 35.65. Intraoperative bleeding: Study group 187.35-90.93 m L, control group 210.29-98.02 mL. The indwelling time of the chest tube: 5.42 to 2.49 days in the study group and 5.35 to 3.18 days in the control group. The number of lymph node dissection: 9.59 to 2.32 in the study group and 9.47 to 2.03 in the control group. Postoperative complications were 2 (11.8%) in the study group and 6 in the control group (30.0%). Post-operative hospitalization days: Study group 7.35-2.03 days, control group 10.12-2.32 days. The operative time of the two groups, the intraoperative blood loss, the time of the indwelling time of the drainage tube and the number of lymph node dissection were not significant (P0.05); the incidence of postoperative complications and the VAS pain score of the study group were lower, and the number of hospitalized days was shorter and the difference was statistically significant (P0.05). Conclusion: The clinical stage 鈪-N2 stage non-small cell lung cancer is safe and feasible after neoadjuvant chemotherapy for non-small cell lung cancer. In the patients with non-small cell lung cancer in stage 鈪-N2 of clinical stage, the patients with non-small cell lung cancer were treated with video-assisted thoracoscopic surgery. Video-assisted thoracoscopic surgery can be selected for patients with non-obvious enlargement and invasion of the mediastinal lymph nodes of the hilar. It is also possible to select the key technology points of video-assisted thoracoscopic surgery. For mediastinal lymph node dissection, the enbloc resection technique, i.e., one-piece resection technique, should be used to avoid lymph node sampling.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2018
【分類號(hào)】：R734.2
本文編號(hào)：2447185
[Abstract]:BACKGROUND & OBJECTIVE: The patients with advanced non-small cell lung cancer (NSCLC) with advanced non-small cell lung cancer (NSCLC) with advanced non-small cell lung cancer are more complicated than the early stage of lung cancer. Is technically and safely possible? Is there an advantage over the traditional thoracotomy? There are still a wide range of disputes at home and abroad. The purpose of this study was to investigate the safety and feasibility of a new adjuvant chemotherapy for non-small cell lung cancer in stage 鈪-N2 non-small cell lung cancer after neoadjuvant chemotherapy, and to evaluate the safety and feasibility of thoracoscopic pulmonary lobectomy after neoadjuvant chemotherapy in stage 鈪-N2 non-small cell lung cancer. And summarize the experience of the operation. Methods:40 patients with non-small cell lung cancer who received neoadjuvant chemotherapy in stage 鈪-N2 and non-small cell lung cancer with pulmonary lobectomy were selected from June 2012 to June 2016, and two groups were randomly divided into two groups:20 patients in the study group and 20 patients with systematic lymph node dissection; In the control group,20 cases of conventional thoracotomy + systematic lymph node dissection were performed. The operative time, the intraoperative blood loss, the indwelling time of the drainage tube, the number of lymph node dissection, the postoperative complications, the number of postoperative hospital stay and the VAS pain score were compared. Results: In the study group,17 cases underwent thoracoscopic lobectomy, one case (1/20,5%) underwent thoracoscopic exploration, and 2 cases (2/20,10%) of transthoracic and pulmonary lobectomy were performed in the study group, and 20 cases of the traditional thoracotomy group successfully completed the lobectomy. There were no perioperative deaths in both groups. The operation time of the two groups was 165.47 and 30.54 in the study group, and the control group was 152.53 to 35.65. Intraoperative bleeding: Study group 187.35-90.93 m L, control group 210.29-98.02 mL. The indwelling time of the chest tube: 5.42 to 2.49 days in the study group and 5.35 to 3.18 days in the control group. The number of lymph node dissection: 9.59 to 2.32 in the study group and 9.47 to 2.03 in the control group. Postoperative complications were 2 (11.8%) in the study group and 6 in the control group (30.0%). Post-operative hospitalization days: Study group 7.35-2.03 days, control group 10.12-2.32 days. The operative time of the two groups, the intraoperative blood loss, the time of the indwelling time of the drainage tube and the number of lymph node dissection were not significant (P0.05); the incidence of postoperative complications and the VAS pain score of the study group were lower, and the number of hospitalized days was shorter and the difference was statistically significant (P0.05). Conclusion: The clinical stage 鈪-N2 stage non-small cell lung cancer is safe and feasible after neoadjuvant chemotherapy for non-small cell lung cancer. In the patients with non-small cell lung cancer in stage 鈪-N2 of clinical stage, the patients with non-small cell lung cancer were treated with video-assisted thoracoscopic surgery. Video-assisted thoracoscopic surgery can be selected for patients with non-obvious enlargement and invasion of the mediastinal lymph nodes of the hilar. It is also possible to select the key technology points of video-assisted thoracoscopic surgery. For mediastinal lymph node dissection, the enbloc resection technique, i.e., one-piece resection technique, should be used to avoid lymph node sampling.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2018
【分類號(hào)】：R734.2
【參考文獻(xiàn)】
相關(guān)期刊論文 前9條
1 葉永強(qiáng);羅忠兵;田克強(qiáng);;單操作孔全胸腔鏡肺葉切除術(shù)10例體會(huì)[J];實(shí)用醫(yī)學(xué)雜志;2013年11期
2 劉倫旭;梅建東;蒲強(qiáng);馬林;朱云柯;任福強(qiáng);車國(guó)衛(wèi);張小龍;;全胸腔鏡支氣管袖式成形肺癌切除的初步探討[J];中國(guó)胸心血管外科臨床雜志;2011年05期
3 張軼;朱余明;鮑熠;劉鴻程;范江;秦嬴;姜格寧;;全胸腔鏡下袖式肺葉切除術(shù)治療支氣管肺癌四例[J];中華外科雜志;2012年09期
4 吳一龍;蔣國(guó)梁;廖美琳;周清華;陸舜;張力;王俊;王綠化;;非小細(xì)胞肺癌ⅢA期N2之處理[J];循證醫(yī)學(xué);2008年02期
5 邱曉光;俞守義;;62例Ⅲ期非小細(xì)胞肺癌新輔助化療的生存分析[J];廣東醫(yī)學(xué);2007年02期
6 劉樹庫;許紹發(fā);駱寶劍;劉志東;李福根;韓毅;;1380例手術(shù)后的非小細(xì)胞肺癌的多因素預(yù)后分析[J];中國(guó)肺癌雜志;2006年05期
7 張志庸,郭峰,崔玉尚,李單青,李力,徐曉輝,戈烽,郭惠琴,李澤堅(jiān);北京協(xié)和醫(yī)院外科治療肺癌生存率變化分析[J];中國(guó)肺癌雜志;2005年02期
8 周清華,劉倫旭,李潞,車國(guó)衛(wèi),楊俊杰,趙雍凡,陳軍,王允,秦建軍,侯梅,宮友陵,盧武勝,李志平;術(shù)前新輔助化療加外科手術(shù)治療Ⅲ期非小細(xì)胞肺癌的隨機(jī)對(duì)照臨床試驗(yàn)[J];中國(guó)肺癌雜志;2001年04期
9 吳一龍,黃植蕃,戎鐵華,楊名添;基于97分期的非小細(xì)胞肺癌術(shù)后分期和生存研究[J];中華腫瘤雜志;1999年05期
，本文編號(hào)：2447185
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2447185.html
最近更新
教材專著
